Market Cap : 13.24 B | Enterprise Value : 12.84 B | PE Ratio : 680.41 | PB Ratio : 30.15 |
---|
NVCR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVCR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NovoCure's Enterprise Value is $12,841.4 Mil. NovoCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was $31.2 Mil. Therefore, NovoCure's EV-to-EBIT for today is 410.94.
During the past 8 years, the highest EV-to-EBIT of NovoCure was 1857.00. The lowest was -1168.20. And the median was -11.90.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. NovoCure's Enterprise Value for the quarter that ended in Dec. 2020 was $18,838.5 Mil. NovoCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was $31.2 Mil. NovoCure's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2020 was 0.17%.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
* The bar in red indicates where NovoCure's EV-to-EBIT falls into.
NovoCure's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 12841.412 | / | 31.249 | |
= | 410.94 |
NovoCure's current Enterprise Value is $12,841.4 Mil.
NovoCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was -3.381 (Mar. 2020 ) + 6.668 (Jun. 2020 ) + 15.022 (Sep. 2020 ) + 12.94 (Dec. 2020 ) = $31.2 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
NovoCure's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2020 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Dec. 2020 ) | = | EBIT | / | Enterprise Value (Q: Dec. 2020 ) |
= | 31.249 | / | 18838.4788 | |
= | 0.17 % |
NovoCure's Enterprise Value for the quarter that ended in Dec. 2020 was $18,838.5 Mil.
NovoCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was -3.381 (Mar. 2020 ) + 6.668 (Jun. 2020 ) + 15.022 (Sep. 2020 ) + 12.94 (Dec. 2020 ) = $31.2 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
No Headline